Nu-Med Plus Inc. (NUMD): Financials
Trailing 12 months ended June 30, 2025
Income statement, cash flow and balance sheet figures for Nu-Med Plus Inc. (NUMD), read directly from the XBRL data the company files with the SEC. Over the trailing twelve months the company reported $0 of revenue. Net loss was $60.8K, or $0.00 per diluted share.
14 fiscal years of history are available, back to 2012.
Frequently asked questions
How much revenue does NUMD make?
Nu-Med Plus Inc. reported $0 of revenue over the trailing twelve months, for the period ended June 30, 2025.
Is NUMD profitable?
Nu-Med Plus Inc. was unprofitable over the trailing twelve months, with a net loss of $60.8K.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.